The safety of gadolinium in patients with stage 3 and 4 renal failure

Creative Commons License

Ergun I., KEVEN K., Uruc I., Ekmekci Y., Canbakan B., Erden I., ...Daha Fazla

NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.21, sa.3, ss.697-700, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 3
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1093/ndt/gfi304
  • Dergi Adı: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.697-700
  • Anahtar Kelimeler: acute renal failure, chronic renal failure, contrast nephropathy, gadolinium, CONTRAST-INDUCED NEPHROPATHY, NEPHROTOXICITY, DIMEGLUMINE, ANGIOGRAPHY, MEDIA
  • Ankara Üniversitesi Adresli: Hayır

Özet

Background. Although there is a well-documented risk of acute renal failure (ARF) with the iodinated contrast agents, intravenous gadolinium-based contrast agents are considered non-nephrotoxic and have been widely used for magnetic resonance imaging (MRI). However, debate continues regarding the safety issue of gadolinium, especially in patients with kidney failure. Therefore, we aimed to evaluate the safety of gadolinium in patients with stage 3 and 4 renal failure as well as risk factors for nephrotoxicity.